MedAxiom, ACC and Novo Nordisk to Advance Care for People with Type 2 Diabetes, Cardiovascular Disease
Global initiative will educate and engage clinicians in providing optimal multidisciplinary care
News | Published: Friday, March 19, 2021 9:00 am
MedAxiom and the ACC, in collaboration with Novo Nordisk A/S, are embarking on a new global program to support improvements in multidisciplinary care for people with Type 2 diabetes. Through the global UNITE (Multidisciplinary Teams In Cardiometabolic Care) program, clinicians across multiple specialties will receive the education and tools needed for an integrated approach to Type 2 diabetes and cardiovascular disease care.
UNITE will be launched in targeted countries around the world in 2021 to promote implementation of the multidisciplinary approach and foster increased collaboration. MedAxiom, along with the American Diabetes Association (ADA), will be instrumental in developing a series of six educational webinars on cardiometabolics, cardiometabolic education modules for the cardiovascular care team and a live cardiometabolic clinic for clinicians. The first program was successfully initiated in the United Arab Emirates in December 2020, with additional countries to be announced later this year.
“As the premier source for cardiovascular performance solutions, MedAxiom looks forward to putting our rich expertise into practice by developing the cardiometabolic clinic operational workflow as part of the UNITE program,” said Ginger Biesbrock, PA-C, MPH, MPAS, FACC, MedAxiom EVP of Care Transformation. “Through this multi-disciplinary cardiometabolic clinical program, MedAxiom, the ACC, Novo Nordisk and the ADA will transform care for patients with Type 2 diabetes and cardiovascular disease around the world.”
Cardiovascular disease is the No. 1 cause of death among people with Type 2 diabetes. While recent clinical guidelines have begun to reflect the increased cardiovascular risk associated with Type 2 diabetes, barriers to achieving optimal care remain. The ACC recognized this in the 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes, which recommends a multidisciplinary approach to managing this high-risk patient group with multiple comorbidities, but additional work is needed to help clinicians implement these recommendations.
“Despite advances in care, people with Type 2 diabetes continue to face a higher risk of death and disability from cardiovascular disease,” said Athena Poppas, MD, FACC, ACC president. “New strategies for managing this complex disease are needed. Through UNITE, we’re meeting that need by providing guidance and tools that can be easily integrated into day-to-day clinical practice to optimize cardiovascular risk through treatment pathways and collaborative management of comorbidities.”
For the latest information on UNITE, visit ACC.org/UNITE.